Efficacy of Irbesartan on Left Ventricular Mass and Arterial Stiffness in Hypertensive Patients
Background: Increased aortic stiffness measured by pulse wave velocity (PWV) and left ventricular hypertrophy (LVH) are independent risk factors of cardiovascular events in hypertensive patients. We have conducted a prospective study to examine the effects of the angiotensin II receptor antagonist (...
Gespeichert in:
| Veröffentlicht in: | The Korean journal of internal medicine 2006-06, Vol.21 (2), p.103 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | kor |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 103 |
| container_title | The Korean journal of internal medicine |
| container_volume | 21 |
| creator | Chang Gyu Park Jeong Cheon Ahn Soon Jun Hong Eung Joo Kim Seung Jin Lee Sung Mi Park Hong Seog Seo Dong Joo Oh |
| description | Background: Increased aortic stiffness measured by pulse wave velocity (PWV) and left ventricular hypertrophy (LVH) are independent risk factors of cardiovascular events in hypertensive patients. We have conducted a prospective study to examine the effects of the angiotensin II receptor antagonist (irbesartan) on PWV and LVH in hypertensive patients. Methods: A total of 52 untreated hypertensive patients (age:53.3±8.0 yrs) were enrolled; they had no evidence of associated cardiovascular complications. Blood pressure, heart rate, aortic PWV and left ventricular mass index (LVMI) by 2-D echocardiography were measured at baseline and after irbesartan treatment (150 mg or 300 mg/day) at 12 weeks and 24 weeks. Results: Blood pressure was significantly decreased after 12 weeks and 24 weeks of treatment compared to baseline (SBP: 134.6±13.3 mmHg, 134.0±11.0 mmHg vs 163.7±13.8 mmHg p |
| format | Article |
| fullrecord | <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_2766496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>2766496</kiss_id><sourcerecordid>2766496</sourcerecordid><originalsourceid>FETCH-kiss_primary_27664963</originalsourceid><addsrcrecordid>eNp9jkEKwjAQRYMoWLQncDMXKKSNjboUqSgoCIrbMq0JDNa0ZKLQ29uFa1cP_uPDG4kokzJPtF6uxyJKs0wnSkk1FTEzVVKqNNWpzCNRFtZSjXUPrYWjrwyjD-igdXAyNsDduOCpfjfo4YzMgO4BWx-MJ2zgGshaZ4aZHBz6zgzCMX0MXDDQcOW5mFhs2MQ_zsRiX9x2h-RJzGXn6YW-L7PVULrR6r_9AtLRQNw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of Irbesartan on Left Ventricular Mass and Arterial Stiffness in Hypertensive Patients</title><source>KoreaMed Synapse</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Chang Gyu Park ; Jeong Cheon Ahn ; Soon Jun Hong ; Eung Joo Kim ; Seung Jin Lee ; Sung Mi Park ; Hong Seog Seo ; Dong Joo Oh</creator><creatorcontrib>Chang Gyu Park ; Jeong Cheon Ahn ; Soon Jun Hong ; Eung Joo Kim ; Seung Jin Lee ; Sung Mi Park ; Hong Seog Seo ; Dong Joo Oh</creatorcontrib><description>Background: Increased aortic stiffness measured by pulse wave velocity (PWV) and left ventricular hypertrophy (LVH) are independent risk factors of cardiovascular events in hypertensive patients. We have conducted a prospective study to examine the effects of the angiotensin II receptor antagonist (irbesartan) on PWV and LVH in hypertensive patients. Methods: A total of 52 untreated hypertensive patients (age:53.3±8.0 yrs) were enrolled; they had no evidence of associated cardiovascular complications. Blood pressure, heart rate, aortic PWV and left ventricular mass index (LVMI) by 2-D echocardiography were measured at baseline and after irbesartan treatment (150 mg or 300 mg/day) at 12 weeks and 24 weeks. Results: Blood pressure was significantly decreased after 12 weeks and 24 weeks of treatment compared to baseline (SBP: 134.6±13.3 mmHg, 134.0±11.0 mmHg vs 163.7±13.8 mmHg p<0.001, DBP: 86.0±10 mmHg, 83.07 mmHg vs 102.4±9.6 mmHg p<0.001, respectively) without significant change in heart rate. LVMI decreased at 12 weeks and at 24 weeks after treatment compared to baseline (from 145.5±35.1 g/m2 at baseline to 137.5±35.4 g/m2 at 12 weeks, p=0.017 and 135.3±35.4 g/m2 at 24 weeks, p=0.008). Aortic PWV was decreased after irbesartan treatment at 12 weeks (from 9.6±2.8 m/sec to 8.7±3.1 m/sec at 12 weeks, p=0.064) and at 24 weeks (from 9.6±2.9 m/sec to 7.7±2.1 m/sec at 24 weeks, p=0.007). Conclusions: Long-term treatment with irbesartan may reduce arterial stiffness and regression of LVH in hypertensive patients. The pleiotropic effects of irbesartan, further decreasing PWV without change of BP between 12 and 24 weeks of treatment, may have favorable vascular effects on arterial stiffness and LVH.</description><identifier>ISSN: 1226-3303</identifier><identifier>EISSN: 2005-6648</identifier><language>kor</language><publisher>대한내과학회</publisher><subject>Angiotensin ; Aortic stiffness ; Hypertension ; Irbesartan ; LVH ; PWV</subject><ispartof>The Korean journal of internal medicine, 2006-06, Vol.21 (2), p.103</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids></links><search><creatorcontrib>Chang Gyu Park</creatorcontrib><creatorcontrib>Jeong Cheon Ahn</creatorcontrib><creatorcontrib>Soon Jun Hong</creatorcontrib><creatorcontrib>Eung Joo Kim</creatorcontrib><creatorcontrib>Seung Jin Lee</creatorcontrib><creatorcontrib>Sung Mi Park</creatorcontrib><creatorcontrib>Hong Seog Seo</creatorcontrib><creatorcontrib>Dong Joo Oh</creatorcontrib><title>Efficacy of Irbesartan on Left Ventricular Mass and Arterial Stiffness in Hypertensive Patients</title><title>The Korean journal of internal medicine</title><addtitle>The Korean Journal of Internal Medicine</addtitle><description>Background: Increased aortic stiffness measured by pulse wave velocity (PWV) and left ventricular hypertrophy (LVH) are independent risk factors of cardiovascular events in hypertensive patients. We have conducted a prospective study to examine the effects of the angiotensin II receptor antagonist (irbesartan) on PWV and LVH in hypertensive patients. Methods: A total of 52 untreated hypertensive patients (age:53.3±8.0 yrs) were enrolled; they had no evidence of associated cardiovascular complications. Blood pressure, heart rate, aortic PWV and left ventricular mass index (LVMI) by 2-D echocardiography were measured at baseline and after irbesartan treatment (150 mg or 300 mg/day) at 12 weeks and 24 weeks. Results: Blood pressure was significantly decreased after 12 weeks and 24 weeks of treatment compared to baseline (SBP: 134.6±13.3 mmHg, 134.0±11.0 mmHg vs 163.7±13.8 mmHg p<0.001, DBP: 86.0±10 mmHg, 83.07 mmHg vs 102.4±9.6 mmHg p<0.001, respectively) without significant change in heart rate. LVMI decreased at 12 weeks and at 24 weeks after treatment compared to baseline (from 145.5±35.1 g/m2 at baseline to 137.5±35.4 g/m2 at 12 weeks, p=0.017 and 135.3±35.4 g/m2 at 24 weeks, p=0.008). Aortic PWV was decreased after irbesartan treatment at 12 weeks (from 9.6±2.8 m/sec to 8.7±3.1 m/sec at 12 weeks, p=0.064) and at 24 weeks (from 9.6±2.9 m/sec to 7.7±2.1 m/sec at 24 weeks, p=0.007). Conclusions: Long-term treatment with irbesartan may reduce arterial stiffness and regression of LVH in hypertensive patients. The pleiotropic effects of irbesartan, further decreasing PWV without change of BP between 12 and 24 weeks of treatment, may have favorable vascular effects on arterial stiffness and LVH.</description><subject>Angiotensin</subject><subject>Aortic stiffness</subject><subject>Hypertension</subject><subject>Irbesartan</subject><subject>LVH</subject><subject>PWV</subject><issn>1226-3303</issn><issn>2005-6648</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9jkEKwjAQRYMoWLQncDMXKKSNjboUqSgoCIrbMq0JDNa0ZKLQ29uFa1cP_uPDG4kokzJPtF6uxyJKs0wnSkk1FTEzVVKqNNWpzCNRFtZSjXUPrYWjrwyjD-igdXAyNsDduOCpfjfo4YzMgO4BWx-MJ2zgGshaZ4aZHBz6zgzCMX0MXDDQcOW5mFhs2MQ_zsRiX9x2h-RJzGXn6YW-L7PVULrR6r_9AtLRQNw</recordid><startdate>20060601</startdate><enddate>20060601</enddate><creator>Chang Gyu Park</creator><creator>Jeong Cheon Ahn</creator><creator>Soon Jun Hong</creator><creator>Eung Joo Kim</creator><creator>Seung Jin Lee</creator><creator>Sung Mi Park</creator><creator>Hong Seog Seo</creator><creator>Dong Joo Oh</creator><general>대한내과학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20060601</creationdate><title>Efficacy of Irbesartan on Left Ventricular Mass and Arterial Stiffness in Hypertensive Patients</title><author>Chang Gyu Park ; Jeong Cheon Ahn ; Soon Jun Hong ; Eung Joo Kim ; Seung Jin Lee ; Sung Mi Park ; Hong Seog Seo ; Dong Joo Oh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_27664963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2006</creationdate><topic>Angiotensin</topic><topic>Aortic stiffness</topic><topic>Hypertension</topic><topic>Irbesartan</topic><topic>LVH</topic><topic>PWV</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang Gyu Park</creatorcontrib><creatorcontrib>Jeong Cheon Ahn</creatorcontrib><creatorcontrib>Soon Jun Hong</creatorcontrib><creatorcontrib>Eung Joo Kim</creatorcontrib><creatorcontrib>Seung Jin Lee</creatorcontrib><creatorcontrib>Sung Mi Park</creatorcontrib><creatorcontrib>Hong Seog Seo</creatorcontrib><creatorcontrib>Dong Joo Oh</creatorcontrib><collection>Korean Studies Information Service System (KISS)</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>The Korean journal of internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang Gyu Park</au><au>Jeong Cheon Ahn</au><au>Soon Jun Hong</au><au>Eung Joo Kim</au><au>Seung Jin Lee</au><au>Sung Mi Park</au><au>Hong Seog Seo</au><au>Dong Joo Oh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Irbesartan on Left Ventricular Mass and Arterial Stiffness in Hypertensive Patients</atitle><jtitle>The Korean journal of internal medicine</jtitle><addtitle>The Korean Journal of Internal Medicine</addtitle><date>2006-06-01</date><risdate>2006</risdate><volume>21</volume><issue>2</issue><spage>103</spage><pages>103-</pages><issn>1226-3303</issn><eissn>2005-6648</eissn><abstract>Background: Increased aortic stiffness measured by pulse wave velocity (PWV) and left ventricular hypertrophy (LVH) are independent risk factors of cardiovascular events in hypertensive patients. We have conducted a prospective study to examine the effects of the angiotensin II receptor antagonist (irbesartan) on PWV and LVH in hypertensive patients. Methods: A total of 52 untreated hypertensive patients (age:53.3±8.0 yrs) were enrolled; they had no evidence of associated cardiovascular complications. Blood pressure, heart rate, aortic PWV and left ventricular mass index (LVMI) by 2-D echocardiography were measured at baseline and after irbesartan treatment (150 mg or 300 mg/day) at 12 weeks and 24 weeks. Results: Blood pressure was significantly decreased after 12 weeks and 24 weeks of treatment compared to baseline (SBP: 134.6±13.3 mmHg, 134.0±11.0 mmHg vs 163.7±13.8 mmHg p<0.001, DBP: 86.0±10 mmHg, 83.07 mmHg vs 102.4±9.6 mmHg p<0.001, respectively) without significant change in heart rate. LVMI decreased at 12 weeks and at 24 weeks after treatment compared to baseline (from 145.5±35.1 g/m2 at baseline to 137.5±35.4 g/m2 at 12 weeks, p=0.017 and 135.3±35.4 g/m2 at 24 weeks, p=0.008). Aortic PWV was decreased after irbesartan treatment at 12 weeks (from 9.6±2.8 m/sec to 8.7±3.1 m/sec at 12 weeks, p=0.064) and at 24 weeks (from 9.6±2.9 m/sec to 7.7±2.1 m/sec at 24 weeks, p=0.007). Conclusions: Long-term treatment with irbesartan may reduce arterial stiffness and regression of LVH in hypertensive patients. The pleiotropic effects of irbesartan, further decreasing PWV without change of BP between 12 and 24 weeks of treatment, may have favorable vascular effects on arterial stiffness and LVH.</abstract><pub>대한내과학회</pub><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1226-3303 |
| ispartof | The Korean journal of internal medicine, 2006-06, Vol.21 (2), p.103 |
| issn | 1226-3303 2005-6648 |
| language | kor |
| recordid | cdi_kiss_primary_2766496 |
| source | KoreaMed Synapse; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Angiotensin Aortic stiffness Hypertension Irbesartan LVH PWV |
| title | Efficacy of Irbesartan on Left Ventricular Mass and Arterial Stiffness in Hypertensive Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T14%3A01%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Irbesartan%20on%20Left%20Ventricular%20Mass%20and%20Arterial%20Stiffness%20in%20Hypertensive%20Patients&rft.jtitle=The%20Korean%20journal%20of%20internal%20medicine&rft.au=Chang%20Gyu%20Park&rft.date=2006-06-01&rft.volume=21&rft.issue=2&rft.spage=103&rft.pages=103-&rft.issn=1226-3303&rft.eissn=2005-6648&rft_id=info:doi/&rft_dat=%3Ckiss%3E2766496%3C/kiss%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=2766496&rfr_iscdi=true |